Copyright © 2020 MarketWatch, Inc. All rights reserved. 2 Top Biotech Stocks to Buy Right Now. 3 Healthcare Stocks That Can … ]In a report released today, Raju Prasad from William Blair maintained a Buy rating on Cellectis SA (CLLS). First Patient Dosed With Cellectis' New Allogeneic UCART123 Product Candidate For Relapsed/Refractory Acute Myeloid Leukemia By Business Wire Jan 15, 2020 4:30 PM EST It offers Gene editing and Immuno-oncology. Have Watchlists? Nom. Since then, CLLS stock has increased by 40.9% and is now trading at $16.11. Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.TALEN® is a registered trademark owned by Cellectis.For further information, please contact:Media contacts: Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, ckasunich@kcsa.comIR contact: Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.comPDF available: http://ml.globenewswire.com/Resource/Download/de9f0231-073e-4080-8204-56495abc5d53This anti-snoring device gives you a peaceful night!NEW YORK, July 21, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.Tip: Try a valid symbol or a specific company name for relevant resultsNasdaqGM - NasdaqGM Real Time Price. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Cellectis against related stocks people have also bought. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. stock information press releases events and webcasts corporate presentations Financial Statements SEC filings Regulated information ... Get the latest on gene-editing innovation, financial and business news from Cellectis with our email alert service. Anti-Snore Device Finally Hits United States Registration on or use of this site constitutes acceptance of our
Real time Cellectis (CLLS) stock price quote, stock graph, news & analysis. Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). EUR
The trading starts at $16.52 and closed at $16.57 throughout the day. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). stock price and detailed information including news, historical charts and realtime prices. The trading session low price was $15.90 and day high was $16.52 on Wednesday, July 29. It offers Gene editing and Immuno-oncology. CELLECTISAct. Find the latest Cellectis S.A. (CLLS) stock quote, history, news and other vital information to help you with your stock trading and investing. Nom. It offers Gene editing and Immuno-oncology. NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report its financial results for the second quarter of 2020 together with a business update on Wednesday, August 5, 2020, after the close of the US market.
We recommend trying out cheaper alternatives like TransferWise. ]Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. By using this site you agree to the
* Copyright © 2020 Insider Inc. and finanzen.net GmbH
Fed’s Evans says the power to get the economy going lies with Congress The announcement will be followed by a conference call at 7:30 AM EDT / 1:30 PM CET on Thursday, August 6, 2020, prior to the open of the US market. How Cellectis (CLLS) Stock Stands Out in a Strong Industry Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. A 10% selloff in the stock market is most likely, says expert who called March lows: ‘Something has to give’ ]Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
: Get the latest CELLECTISAct. Cellectis S.A. (NASDAQ:CLLS) changes shares on Wednesday trading session, with a change of -2.35% or -$0.39 shares. Harmonic stock jumps as results beat, strong outlook issued